CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback